Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio
1.10.2019 09:00:00 EEST | Business Wire | Press release
Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of PIXUVRI to Servier. Servier commercialized PIXUVRI globally, in all countries where the drug was approved under an exclusive license from CTI BioPharma.
“The acquisition of PIXUVRI is an important step towards Servier’s long-term strategy to become a key player in oncology. Within oncology, one of our key focuses is hematology, and we now have two medicines that are marketed globally alongside a strong and innovative pipeline of drug candidates which includes CAR-T therapies,” said Claude Bertrand, Executive VP, Global Head of R&D at Servier. “As part of our strategy, we are committed to invest 50% of our R&D budget in oncology.”
Non-Hodgkin lymphoma (NHL) is a blood cancer that affects the lymphatic system, it can occur in different parts of the body from the lymph nodes in the neck to the liver or spleen, but also in other organs such as the stomach, small bowel, bones, brain, testicles or skin.1 Globally there are over 500,000 new cases of NHL a year; it is both the 11th most commonly diagnosed cancer and cause of cancer death.2
“We have a strong commitment to providing effective solutions for patients living with cancer. PIXUVRI is an effective treatment that received standard European marketing authorization in June, and today marks a new step towards achieving Servier’s long term goals. We will ensure that patients will continue to have access to PIXUVRI”, said Eric Falcand, VP, Global Head of Business Development & Licensing at Servier. “We are continuing to strengthen our oncology portfolio through our R&D efforts and strategic alliances.”
#ENDS#
About PIXUVRI (pixantrone)
PIXUVRI is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. This means that the cancer cells cannot divide and eventually die.3 PIXUVRI is indicated in the European Union as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.3 PIXUVRI is also approved in Iceland, Israel, Liechtenstein, Myanmar, Norway, Pakistan, Russia and Ukraine.
PIXUVRI is mentioned in the ESMO guidelines as an anthracycline-like drug with reduced cardiotoxicity, which demonstrated some efficacy in heavily treated patients.4
More detail is available in the summary of the European public assessment report (EPAR) on the EMA website at www.ema.europa.eu.
About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generics) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are twelve molecular entities in clinical development in this area, targeting gastro-intestinal and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics and immune targeted therapies, to deliver life-changing medicines to patients.
More information: www.servier.com
Follow us on Social Media: LinkedIn I Facebook I Twitter
1 Cancer Research UK. What is NHL cancer. Available at http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/what-is-lymphoma. Last accessed September 2019.
2 World Health Organisation. Globocan 2018. Non-Hodgkin lymphoma. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/34-Non-hodgkin-lymphoma-fact-sheet.pdf. Last accessed September 2019.
3 European Medicines Agency. Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/pixuvri-epar-product-information_en.pdf. Last accessed September 2019.
4 Tilly H et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology (2015). Volume 26 (suppl 5); v116-v125. Available at: http://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma. Last accessed September 2019.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190930005875/en/
Contact information
Servier Media Relations
Sonia Marques
sonia.marques@servier.com
Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Jean-Clément Vergeau
jean-clement.vergeau@servier.com
Tel. +33 (0)1 55 72 46 16 / + 33 (0) 6 79 56 75 96
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pure Lithium Announces Unprecedented Cycling Results From Its Advanced Anode™ Lithium Metal Battery Technology26.8.2026 14:00:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, today announced that our Advanced Anode™ battery, technology developed specifically to enable ultra-long cycling, has achieved more than 9,315 cycles. The cells continue to cycle in the Company's laboratory. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826201214/en/ To the Company’s knowledge, no other lithium metal battery in development has achieved such results under equivalent testing conditions. The performance of the Company’s battery, achieved with negligible capacity fade, far exceeds today’s commercial lithium-ion battery cycling requirements across numerous applications, where performance typically ranges from 250 to 2,000 cycles, depending on the application. These results were achieved at 100% depth of discharge, and charge rates of 1C: 1C.1 “The results of Pure Lithium’s cycling performance are disruptive. Cycle life
Infopro Digital Automotive Highlights Its Industry-Leading Datasets at Automechanika 202626.8.2026 11:02:00 EEST | Press release
Infopro Digital Automotive, leader in data and software for the automotive market, announces its participation in Automechanika 2026, the world’s leading trade fair for the automotive industry. After completing several significant acquisitions over the past years, including Eucon, GiPA, and Aurelis last September, the company will attend this year’s trade show with a consolidated offering, built upon its trusted industry-leading datasets. Infopro Digital Automotive now addresses every automotive vertical from independent workshops to parts, tyres and car manufacturers, through the whole network of aftermarket distribution professionals, thus delivering to them key data and integrated digital solutions to power strategic decisions at every step of the vehicle lifecycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826133342/en/ Infopro Digital Automotive’s unmatched dataset portfolio will be presented at Automechanika 20
NIPPON KINZOKU Establishes Mass Production of Ultra-Thin and Narrow Stainless Steel for Insulin Needles26.8.2026 11:01:00 EEST | Press release
NIPPON KINZOKU CO., LTD. (Headquarters: Minato-ku, Tokyo; President: Yasushi Shimokawa; TOKYO: 5491) is pleased to announce the commencement of mass production for its "Ultra-thin and narrow-width stainless steel" optimized for laser welding in ultra-fine insulin needles. In response to growing global demand, the company has established a stable supply system for these high-quality materials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826770424/en/ The scale of the global diabetes crisis is expanding. In line with this trend, the global demand for insulin needles continues to escalate. Furthermore, insulin delivery is evolving toward "painless" experiences that reduce patient burden. Modern designs prioritize minimizing pain and bruising, leading to the widespread adoption of ultra-fine needles. This trend is further supported by the growing popularity of compact, portable pen injectors. Additionally, the global rise
VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data26.8.2026 11:00:00 EEST | Press release
VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1 clinical trial. VirTus has worked on the APL-10456 programme for more than five years, conducting more than 20 preclinical studies to support the selection, development and progression of the candidate, testing the cross-species immunogenicity and efficacy. This work included evaluating the efficacy of several vaccine candidates in mouse models of rhinovirus infection, helping to select APL-10456 and establish early proof of concept and generating preclinical evidence that informed its progression into first-in-human clinical development. APL-10456 is a first-in-class, adjuvanted recombinant protein subunit
Xsolla President Chris Hewish Debuts “Durable Advantage” at Gamescom 202626.8.2026 10:00:00 EEST | Press release
Xsolla, a leading global commerce company, today announced Durable Advantage: Five Pillars of the Modern Game Business, a new book authored by Chris Hewish, President of Xsolla, launching at Gamescom 2026 in Cologne. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826628682/en/ Graphic: Xsolla Xsolla's integrated strategy brings together global payments, direct-to-consumer commerce, backend infrastructure, and AI-powered development tools into a unified operating model designed to help studios launch, operate, and scale more efficiently. Rather than relying on disconnected commerce, engagement, and backend systems, developers can activate new capabilities through a common platform foundation that reduces complexity, accelerates deployment, and creates a more durable foundation for long-term growth. The strategic framework behind this vision is outlined in Durable Advantage. "There are two kinds of game companies, renters a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom